Akari Therapeutics (NQ: AKTX )

1.600 USD +0.030 (+1.91%)

Official Closing Price Updated: 4:55 PM EST, Nov 30, 2020 Add to My Watchlist

Price and Volume

Volume	158,700
Open	1.590
Bid (Size)	1.590 (5)
Ask (Size)	1.620 (9)
Prev. Close	1.570
Today's Range	1.580 - 1.650
52wk Range	0.8700 - 2.790
Shares Outstanding	15,256,933
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29

October 27, 2020

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

October 06, 2020

Performance

YTD	-8.05%	-8.05%
1 Month	+4.58%	+4.58%
3 Month	-6.98%	-6.98%
6 Month	-27.27%	-27.27%
1 Year	-25.93%	-25.93%

More News

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan

October 01, 2020

Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference

September 29, 2020

Akari Therapeutics to Participate in Two September Virtual Investor Conferences

September 10, 2020

Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress

September 01, 2020

Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia

August 31, 2020

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan

August 12, 2020

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

July 01, 2020

Akari Therapeutics Announces Appointment of Chief Financial Officer

July 01, 2020

Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress

May 29, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.